

Yasuhiro TAKEUCHI

Yasuhiro Takeuchi MD, PhD is Director of Toranomon Hospital Endocrine Center.

He graduated from the University of Tokyo in 1982. He was engaged in a biochemical research of proteoglycans at Bone Research Branch of NIDR, NIH from 1988 to 1990, and his supervisor was Dr. Vincent C Hascall. After spending valuable time in the University of Tokyo School of Medicine for 12 years in collaboration with Drs. Toshio Matsumoto and Seiji Fukumoto, he was promoted to the present position. His main research interests at present are 1) metabolic bone diseases due to several endocrine disorders and several common diseases including chronic kidney disease and type 2 diabetes mellitus and 2) crosstalk between glucose metabolism and bone biology. Other research interests are bone cell biology, diagnosis and treatment of metabolic bone diseases and clinical endocrinology in general.

Selected recent publications

1. Okazaki R, Ozono K, Fukumoto S, Inoue D, Yamauchi M, Minagawa M, Michigami T, Takeuchi Y, Matsumoto T, Sugimoto T.: Assessment criteria for vitamin D deficiency/insufficiency in Japan: proposal by an expert panel supported by the Research Program of Intractable Diseases, Ministry of Health, Labour and Welfare, Japan, the Japanese Society for Bone and Mineral Research and the Japan Endocrine Society [Opinion].

J Bone Miner Metab. 2016 Nov 23. [Epub ahead of print] PMID: 27882481

2. Takeuchi Y, Kuroda T, Sugimoto T, Shiraki M, Nakamura T.: Renal Phosphate Reabsorption is Correlated with the Increase in Lumbar Bone Mineral Density in Patients Receiving Once-Weekly Teriparatide.

Calcif Tissue Int. 98(2):186-192, 2016.

3. Fukumoto S, Ozono K, Michigami T, Minagawa M, Okazaki R, Sugimoto T, Takeuchi Y, Matsumoto T.: Pathogenesis and diagnostic criteria for rickets and osteomalacia-proposal by an expert panel supported by the Ministry of Health, Labour and Welfare, Japan, the Japanese Society for Bone and Mineral Research, and the Japan Endocrine Society.

J Bone Miner Metab. 2015; 33(5):467-73. doi: 10.1007/s00774-015-0698-7.

4. Takeuchi Y, Hamaya E, Taketsuna M, Sowa H.: Safety of 3-year raloxifene treatment in Japanese postmenopausal women aged 75 years or older with osteoporosis: A postmarketing surveillance study.

Menopause. 2015; 22(10):1134-7. doi: 10.1097/GME.0000000000000441.

5. Tamiya H, Miyakawa M, Takeshita A, Miura D, Takeuchi Y.: Ultrasonographic evaluation of parathyroid hyperplasia in multiple endocrine neoplasia type 1: Positive correlation between parathyroid volume and circulating parathyroid hormone concentration.

J Bone Miner Metab. 2015 33(5):523-9. doi: 10.1007/s00774-014-0614-6.

6. Tanaka S, Adachi T, Kuroda T, Nakamura T, Shiraki M, Sugimoto T, Takeuchi Y, Saito M, Bilezikian JP.: New simulation model for bone formation markers in osteoporosis patients treated with once-weekly teriparatide

Bone Research 2014; 2, 14043; doi:10.1038/boneres.2014.43

7. Murakami N, Takeshita A, Suzuki H, Iizuka T, Kikuchi D, Matsui A, Kaise M, Miura D, Kinowaki K, Ohashi K, Takeuchi Y: Hidden culprit of primary hyperparathyroidism.

J Clin Endocrinol Metab. 2012; 97(10):3410-3411. doi: 10.1210/jc.2012-2190. PMID: 22767637

8. Inose H, Ochi H, Kimura A, Fujita K, Xu R, Sato S, Iwasaki M, Takeuchi Y, Fukumoto S, Saito K, Nakamura T, Siomi H, Ito H, Arai Y, Shinomiya K, Takeda S:

A novel microRNA regulatory mechanism of osteoblast differentiation

Proc Natl Acad Sci USA, 2009; 106(49):20794-20799.

9. Sato S, Hanada R, Kimura A, Abe T, Matsumoto T, Iwasaki M, Inose H, Ida T, Mieda M, Takeuchi Y, Fukumoto S, Fujita T, Kato S, Kangawa K, Kojima M, Shinomiya K, Takeda S.: Central control of bone remodeling by neuromedin U.

Nat Med. 2007; 13(10):1234-1240.

10. Fukushima N, Hanada R, Teranishi H, Fukue Y, Tachibana T, Ishikawa H, Takeda S, Takeuchi Y, Fukumoto S, Kangawa K, Nagata K, and Kojima M: Ghrelin directly regulates bone formation.

J Bone Miner Res 2005; 20 (5):790-798.

11. Kinoshita Y, Taguchi M, Takeshita A, Miura D, Tomikawa S, and Takeuchi Y: 1,25-Dihydroxyvitamin D suppresses circulating levels of parathyroid hormone in a patient with primary hyperparathyroidism and coexistent sarcoidosis.

J Clin Endocrinol Metab 2005; 90 (12):6727-6731.

12. Shimada T, Kakitani M, Yamazaki Y, Hasegawa H, Takeuchi Y, Fujita T, Fukumoto S, Tomizuka

K, and Yamashita T: Targeted ablation of *Fgf23* demonstrates an essential physiological role of FGF23 in phosphate and vitamin D metabolism

J Clin Invest, 2004; 113 (4):561-568.

13. Shimada T, Mizutani S, Muto, Yoneya T, Hino R, Takeda S, Takeuchi Y, Fujita T, Fukumoto S, and Yamashita T.: Cloning and characterization of FGF23 as a causative factor of tumor-induced osteomalacia.

Proc Natl Acad Sci USA 2001; 99(11): 6500-5.